Sinus Lift: Saving Time and Reducing Morbidity

Tooth Loss Clinical Trial

— SmartLiftRER  

Official title:

Efficacy of a Novel Simplified, Minimally-invasive Procedure for Sinus Floor Elevation in the Atrophic Posterior Maxilla: a Multicenter, Randomized Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02415946
• Other study ID #: PRUA1GR-2013-00000168
• Status: Completed
• Phase: N/A
• First received: December 2, 2014
• Last updated: February 22, 2018
• Start date: February 2015
• Est. completion date: January 2018

Study information

• Verified date: February 2018
• Source: University Hospital of Ferrara
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

BACKGROUND Tooth loss impairs the OHRQoL. Dental implants have expanded treatment options of edentulous patients and improved their OHRQoL, however, in the posterior maxillary sextants the possibility to place implants of desired length and diameter could be limited. lSFE and tSFE represent two surgical options to vertically enhance the available bone in the edentulous posterior maxilla. Invasivity, relevant postoperative discomfort, high costs, and long times needed for the finalization of the prosthetic rehabilitation, however, strongly limit the indications of lSFE and support the need for less traumatic procedures with similar clinical effectiveness and reduced morbidity. In 2008, the investigators proposed a user-friendly, safe, predictable and effective minimally-invasive procedure for tSFE, namely the Smart Lift technique.

AIMS/OBJECTIVES The general aim of the present project is to validate the Smart Lift technique as a simplified and minimally-invasive procedure for the implant-supported rehabilitation of patients with edentulous, atrophic maxillary posterior sextants.

METHODS In a multicenter RCT study design, the reconstructive (clinical) and patient-centered outcomes of tSFE performed according to the Smart Lift technique will be compared with those of conventional lSFE.

EXPECTED RESULTS The Smart Lift technique should allow for a significant reduction of treatment time, post-surgery complications and costs and an increase in the satisfaction perceived by the edentulous patient with implant-supported rehabilitation, while maintaining a clinical efficacy as well as a similar or lower morbidity and discomfort when compared to lSFE. In other words, the investigators expect that more favorable risk-benefit and cost-utility ratio, as well as a better performance in terms of pain, comfort, physical, social and psychological effects of oral health, and issues concerning the OHRQoL, will be observed for the Smart Lift technique compared to lSFE.

List of Acronyms (in alphabetical order) OHRQoL: Oral Health - Related Quality of Life lSFE:

sinus floor elevation with a lateral approach RCT: randomized controlled trial tSFE: sinus floor elevation with transcrestal approach

Recruitment information / eligibility

• Status: Completed
• Enrollment: 57
• Est. completion date: January 2018
• Est. primary completion date: January 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patient-specific

• age= 21 years;

• good physical status (ASA1 and ASA2 according to Physical Status Classification System) (American Society of Anesthesiologists);

• systemic and local conditions compatible with implant placement and sinus floor elevation procedures;

• indication to a fixed, implant-supported prosthetic rehabilitation with sinus floor elevation as part of the comprehensive oral rehabilitation plan;

• patient willing and fully capable to comply with the study protocol.

Site-specific For a site to be considered as experimental (and thus included for analysis), the following criteria must be fulfilled:

• at least 6 months elapsed from tooth/teeth loss;

• residual bone height (as radiographically assessed) =3 mm and =6 mm;

• receiving an implant 3.5 ÷ 5 mm wide, = 8 mm long and at least 5 mm longer than the residual bone height.

Exclusion Criteria:

• current heavy smoking (= 20 cigarettes/day for = 6 months prior to and at the time of the surgical procedure);

• untreated periodontal disease prior to implant placement;

• history of radiation therapy in the head and neck area;

• history of chemotherapy;

• systemic disease or conditions with a documented effect on bone metabolism and/or osseous healing;

• past (within 6 months prior to enrollment in the study) or current treatment with any medication with a documented effect on bone metabolism and/or osseous healing;

• physical or mental handicap that can interfere with adherence to the study procedures and adequate hygienic compliance;

• documented allergy to dental materials involved in the experimental protocol;

• pregnancy or lactation;

• history of drug or alcohol abuse.

Moreover, participants will be exited from the study immediately upon:

• request to withdraw from further participation;

• development of acute dental, peri-implant or oral conditions requiring treatment;

• development of conditions conflicting with the exclusion criteria listed above;

• failure to comply with study instructions/requirements.

Site-specific

• presence of endodontic lesions at teeth adjacent to the implant site;

• previous bone augmentation/preservation procedures at the designated implant areas;

• diagnosis of maxillary sinusitis at the experimental quadrant;

• need for concomitant lateral/vertical bone reconstructive procedures other than maxillary sinus floor elevation.

Related Conditions & MeSH terms

• Atrophy
• Bone Atrophy
• Tooth Loss

Intervention

Procedure:
• Sinus floor augmentation (lateral)

• Sinus floor augmentation (transcrestal)

Locations

Country	Name	City	State
Italy	University-Hospital	Ferrara
Italy	University-Hospital	Modena

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital of Ferrara	University of Modena and Reggio Emilia

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Vertical extent of sinus lift	At each observation interval, the vertical extent of sinus lift will be measured as the distance (in mm) between the sinus floor and the most apical portion of the radiopaque area in the mid CT/CBCT section including the implant.	week +48
Secondary	Implant survival	At each observation interval, implant survival will be recorded as the persistence of the implant in the oral cavity with absence of mobility (defined as the absence of vertical, lateral and rotational movements of the implant). When evaluating multiple implants splinted by prosthetic restorations, all implants supporting the prosthesis will be considered as failed or survived if the prosthesis is mobile or not mobile, respectively.	week +48
Secondary	Type and incidence of surgical and post-surgical complications	The incidence of membrane perforation will be evaluated by the Valsalva maneuver (for tSFE) or visually (for lSFE). Other surgical or post-surgical complications associated with the sinus lift procedure, including Benign Paroxysmal Positional Vertigo (BPPV), post-operative infection, post-operative haemorrhage, nasal bleeding, blocked nose, either assessed by the operator or reported by the patient, will be also recorded.	week +48
Secondary	Level of post-operative pain	The level of pain perceived by the patient (VASpain) will be recorded daily (evening) for 14 days following surgery on a 100-mm visual analogue scale (VAS) (ranging from "0 - no pain" to "100 - intolerable pain").	week +2
Secondary	type and dosage of post-surgery medications	The patient will self-report the dosage of rescue anti-inflammatory drug (i.e. number of ibuprofen 600 mg tablets) assumed from the 1st to the 14th postoperative day, as well as the assumption of other types of drugs (e.g. antibiotics).	week +2
Secondary	Costs arised from the realization of the surgical procedure and during the postoperative period	Costs arised (i) from the realization of the surgical procedure (e.g., pre-operative exams, materials), and (ii) during the postoperative period (e.g., patient post-surgical monitoring, management of post-surgical complications, and limitations in daily activities caused by surgery) will be evaluated for each patient.; Rather than with monetary units, costs will be compared between treatment groups using tSFE/lSFE ratios.	week +48
Secondary	radiographic height of the graft over the implant apex	The height of the graft apical to the implant apex will be measured as the distance (in mm) occupied by a radiopaque area between the implant apex and the sinus floor as assessed at the mid portion of the implant on the mid CT/CBCT section including the implant.	week +48
Secondary	General health-related quality of life as assessed by the Short Form Health Survey (SF-36) questionnaire	A validated, self-administered questionnaire will be used to assess the general health - related quality of life (GHrQoL) immediately before surgery and at week +48. To assess GHrQoL, the Short Form health survey (SF-36) questionnaire (Ware & Sherbourne 1992) will be used.	day 0, week +48
Secondary	Oral health-related quality of life as assessed by the Oral Health Impact Profile (OHIP-20) questionnaire	A validated, self-administered questionnaire will be used to assess the oral health - related quality of life (OHrQoL) immediately before surgery and at week +48. To assess OHrQoL, the Oral Health Impact Profile (OHIP)-20 questionnaire (Allen & Locker 2002, Awad et al. 2003) will be used.	day 0, week +48